Bharat Biotech, which has received a government purchase order for supply of 55 lakh doses of Covaxin, a COVID-19 vaccine, will pay compensation to recipients in case of any ‘serious adverse’ effects experienced after receiving the antidote. This information is also mentioned in the consent form which has to be signed by the vaccine recipient.
In phase 1 and 2 clinical trials, Covaxin has demonstrated the ability to produce antidotes against COVID-19 and the clinical efficacy of the vaccine is still being studied in phase 3 clinical trials. The company is liable to pay compensation to people in case of serious side effects caused by the vaccine administered while in the clinical trial mode.
Covaxin is India’s totally indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and National Institute of Virology. The vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) bio containment facility.